Tecartus

Tecartus is a cancer medicine used to treat: - adults with mantle cell lymphoma (a cancer of B cells, a type of white blood cell) when the cancer has come back after two or more previous treatments, including a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor; - adults 26 years of age and older with acute lymphoblastic leukaemia (another cancer of B cells) when the cancer has come back or did not respond to previous treatments. These type of B-cell cancers are rare, and Tecartus was designated an ‘ [orphan medicine’](/en/medicines/human/orphan-designations/eu-3-19-2220) (a medicine used in rare diseases) for mantle cell lymphoma on [13 November 2019](/en/medicines/human/orphan-designations/eu-3-19-2220) and for acute lymphoblastic leukaemia on [19 October 2020](/en/medicines/human/orphan-designations/eu-3-20-2344). Tecartus contains the active substance brexucabtagene autoleucel, which consists of genetically modified white blood cells.